InMed Pharmaceuticals Inc.
INM
$2.76
$0.010.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.59% | -10.36% | 40.22% | -44.48% | 13.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.59% | -10.36% | 40.22% | -44.48% | 13.42% |
| Cost of Revenue | 22.98% | -28.96% | -12.42% | 10.30% | 4.96% |
| Gross Profit | -39.34% | 42.21% | 2,227.36% | -70.32% | 50.39% |
| SG&A Expenses | -3.28% | 13.90% | 9.49% | -13.87% | -2.73% |
| Depreciation & Amortization | -4.56% | -3.62% | -0.36% | 2.43% | 8.09% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.75% | 12.67% | -14.39% | 16.44% | -6.73% |
| Operating Income | -17.77% | -29.42% | 33.15% | -289.11% | 16.42% |
| Income Before Tax | -23.10% | -74.20% | 33.86% | -473.56% | 13.70% |
| Income Tax Expenses | -- | -- | -- | 294.44% | -- |
| Earnings from Continuing Operations | -23.10% | -74.20% | 33.86% | -472.61% | 13.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.10% | -74.20% | 33.86% | -472.61% | 13.76% |
| EBIT | -17.77% | -29.42% | 33.15% | -289.11% | 16.42% |
| EBITDA | -18.47% | -30.52% | 33.85% | -322.26% | 17.02% |
| EPS Basic | 46.01% | 1.71% | 82.25% | -98.36% | 70.14% |
| Normalized Basic EPS | 46.01% | 1.71% | 82.25% | -98.69% | 70.12% |
| EPS Diluted | 46.01% | 1.71% | 82.25% | -98.36% | 70.14% |
| Normalized Diluted EPS | 46.01% | 1.71% | 82.25% | -98.69% | 70.12% |
| Average Basic Shares Outstanding | 128.05% | 77.20% | 272.66% | 188.57% | 188.82% |
| Average Diluted Shares Outstanding | 128.05% | 77.20% | 272.66% | 188.57% | 188.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |